Can-Fite BioPharma Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CANF research report →
Companywww.canfite.com
Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
- CEO
- Pnina Fishman
- IPO
- 2012
- Employees
- 5
- HQ
- Petah Tikva, IL
Price Chart
Valuation
- Market Cap
- $1.86M
- P/E
- -832.10
- P/S
- 22399.72
- P/B
- 1017.44
- EV/EBITDA
- -1237.86
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1815.22%
- Net Margin
- -1794.62%
- ROE
- -141.01%
- ROIC
- -101.13%
Growth & Income
- Revenue
- $408.21K · -39.43%
- Net Income
- $-9,905,965 · -25.71%
- EPS
- $-12.03 · -1013.89%
- Op Income
- $-10,028,933
- FCF YoY
- -18.06%
Performance & Tape
- 52W High
- $23.40
- 52W Low
- $2.83
- 50D MA
- $3.23
- 200D MA
- $6.99
- Beta
- 0.03
- Avg Volume
- 1.17M
Get TickerSpark's AI analysis on CANF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 25, 26 | Tamir Ilan | other | 16,000 |
| Mar 18, 26 | Regev Guy | other | 0 |
| Feb 8, 17 | Regev Guy | other | 16 |
| Jun 15, 20 | Regev Guy | other | 200 |
| Aug 1, 23 | Regev Guy | other | 2,166 |
| Aug 7, 24 | Regev Guy | other | 2,166 |
| Apr 25, 26 | Regev Guy | other | 16,000 |
| Jun 22, 21 | Bornstein Yoseph | other | 200 |
| Aug 1, 23 | Bornstein Yoseph | other | 2,166 |
| Aug 7, 24 | Bornstein Yoseph | other | 2,166 |
Our CANF Coverage
We haven't published any research on CANF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CANF Report →